Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs Pfizer Inc (PFE) Price & Performance

KraneShares Hang Seng TECH Index ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

KraneShares Hang Seng TECH Index ETF vs Pfizer Inc — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $13.27, while Pfizer Inc trades at $24.93 (market cap $141.06B). The key difference: Pfizer Inc pays a 6.95% dividend while KraneShares Hang Seng TECH Index ETF pays none, and Pfizer Inc is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.

KTECPFE
Sector
Sector/ThematicHealth
52-Week High
$19.51$28.56
52-Week Low
$12.00$23.29
Market Cap
$141.06B
Volume
29,869,932
Enterprise Value
$191.72B
Dividend Yield
6.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KraneShares Hang Seng TECH Index ETF

KTEC stock is trading at $13.28, up 2.23% today, showing positive momentum. The stock's technical picture indicates recent strength, though key financial ratios including P/E, P/S, and profitability metrics are currently unavailable for analysis. No recent earnings data or business developments are accessible to provide fundamental context.

Investment outlook remains unclear due to insufficient financial data. The primary opportunity lies in the stock's recent price appreciation, while risks include limited transparency on company fundamentals and the absence of analyst coverage or institutional positioning data to validate current valuation levels.

Pfizer Inc

Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.

The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About KraneShares Hang Seng TECH Index ETF

KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.

Read more on KTEC

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE